Company: SVV
Filing Date: 2025-05-16
Form Type: 424B5
Source: 0001193125-25-121233
Chunk: 22

Company: Savers Value Village, Inc.
Filing Date: 2025-05-16
Form: 424B5
Chunk 22
---
 ours who is also an officer, director,
employee, agent, stockholder, member, partner or affiliate of the Ares Funds or their affiliates will be liable to us or our stockholders for breach of any fiduciary duty by reason of the fact that any such individual directs, or communicates
information regarding, a corporate opportunity to the Ares Funds or their affiliates, instead of to us. For example, a director of our company who also serves as an officer, director, employee, agent, stockholder, member, partner or affiliate of the
Ares Funds or their affiliates, or any of their respective portfolio companies or affiliated or managed funds, investment vehicles or accounts, may pursue the acquisition of a business that our company would also have been interested in purchasing.
These potential conflicts of interest could have a material adverse effect on our business, financial condition, results of operations or prospects if attractive corporate opportunities are allocated by an Ares Fund to itself or to the Ares
Funds’ affiliates or their respective portfolio companies or affiliated or managed funds, investment vehicles or accounts instead of to us. A description of our obligations related to corporate opportunities under our certificate of
incorporation are more fully described in “Description of Capital Stock—Corporate Opportunity” in the accompanying prospectus.

S-12

CONCURRENT SHARE REPURCHASE

Subject to the completion of this offering, we intend to purchase from the underwriters 2,258,132 shares of our common stock at a price per
share equal to the price per share to be paid by the underwriters to the selling stockholders. The terms and conditions of the Concurrent Share Repurchase were reviewed and approved by an independent committee of our board of directors, with the
input of independent counsel. The Concurrent Share Repurchase will be funded from our existing cash on hand and is not part of our existing share repurchase program authorized on November 9, 2023. The underwriters will not receive any
compensation for the shares being repurchased by us.

S-13

USE OF PROCEEDS

The selling stockholders are offering all of the shares of our common stock being sold in this offering, including any shares that may be sold
in connection with the exercise of the underwriters’ option to purchase additional shares, and will receive all of the net proceeds from the sales of shares of our common stock being sold in this offering. See “Selling Stockholders.”
We are not selling any shares of our common stock in this offering and we will not receive any proceeds from